1340 related articles for article (PubMed ID: 28031369)
1. Mapping the Human Memory B Cell and Serum Neutralizing Antibody Responses to Dengue Virus Serotype 4 Infection and Vaccination.
Nivarthi UK; Kose N; Sapparapu G; Widman D; Gallichotte E; Pfaff JM; Doranz BJ; Weiskopf D; Sette A; Durbin AP; Whitehead SS; Baric R; Crowe JE; de Silva AM
J Virol; 2017 Mar; 91(5):. PubMed ID: 28031369
[TBL] [Abstract][Full Text] [Related]
2. A new quaternary structure epitope on dengue virus serotype 2 is the target of durable type-specific neutralizing antibodies.
Gallichotte EN; Widman DG; Yount BL; Wahala WM; Durbin A; Whitehead S; Sariol CA; Crowe JE; de Silva AM; Baric RS
mBio; 2015 Oct; 6(5):e01461-15. PubMed ID: 26463165
[TBL] [Abstract][Full Text] [Related]
3. Analysis of Individuals from a Dengue-Endemic Region Helps Define the Footprint and Repertoire of Antibodies Targeting Dengue Virus 3 Type-Specific Epitopes.
Andrade DV; Katzelnick LC; Widman DG; Balmaseda A; de Silva AM; Baric RS; Harris E
mBio; 2017 Sep; 8(5):. PubMed ID: 28928210
[TBL] [Abstract][Full Text] [Related]
4. Isolation of dengue virus-specific memory B cells with live virus antigen from human subjects following natural infection reveals the presence of diverse novel functional groups of antibody clones.
Smith SA; de Alwis AR; Kose N; Jadi RS; de Silva AM; Crowe JE
J Virol; 2014 Nov; 88(21):12233-41. PubMed ID: 25100837
[TBL] [Abstract][Full Text] [Related]
5. Beyond Neutralizing Antibody Levels: The Epitope Specificity of Antibodies Induced by National Institutes of Health Monovalent Dengue Virus Vaccines.
Swanstrom JA; Nivarthi UK; Patel B; Delacruz MJ; Yount B; Widman DG; Durbin AP; Whitehead SS; De Silva AM; Baric RS
J Infect Dis; 2019 Jun; 220(2):219-227. PubMed ID: 30895307
[TBL] [Abstract][Full Text] [Related]
6. Dissecting the human serum antibody response to secondary dengue virus infections.
Patel B; Longo P; Miley MJ; Montoya M; Harris E; de Silva AM
PLoS Negl Trop Dis; 2017 May; 11(5):e0005554. PubMed ID: 28505154
[TBL] [Abstract][Full Text] [Related]
7. Functional Transplant of a Dengue Virus Serotype 3 (DENV3)-Specific Human Monoclonal Antibody Epitope into DENV1.
Messer WB; Yount BL; Royal SR; de Alwis R; Widman DG; Smith SA; Crowe JE; Pfaff JM; Kahle KM; Doranz BJ; Ibarra KD; Harris E; de Silva AM; Baric RS
J Virol; 2016 May; 90(10):5090-5097. PubMed ID: 26962223
[TBL] [Abstract][Full Text] [Related]
8. Complexity of Neutralizing Antibodies against Multiple Dengue Virus Serotypes after Heterotypic Immunization and Secondary Infection Revealed by In-Depth Analysis of Cross-Reactive Antibodies.
Tsai WY; Durbin A; Tsai JJ; Hsieh SC; Whitehead S; Wang WK
J Virol; 2015 Jul; 89(14):7348-62. PubMed ID: 25972550
[TBL] [Abstract][Full Text] [Related]
9. Human dengue virus serotype 2 neutralizing antibodies target two distinct quaternary epitopes.
Gallichotte EN; Baric TJ; Yount BL; Widman DG; Durbin A; Whitehead S; Baric RS; de Silva AM
PLoS Pathog; 2018 Feb; 14(2):e1006934. PubMed ID: 29481552
[TBL] [Abstract][Full Text] [Related]
10. Dimerization of Dengue Virus E Subunits Impacts Antibody Function and Domain Focus.
Thomas A; Thiono DJ; Kudlacek ST; Forsberg J; Premkumar L; Tian S; Kuhlman B; de Silva AM; Metz SW
J Virol; 2020 Aug; 94(18):. PubMed ID: 32611757
[TBL] [Abstract][Full Text] [Related]
11. A Dengue Virus Serotype 1 mRNA-LNP Vaccine Elicits Protective Immune Responses.
Wollner CJ; Richner M; Hassert MA; Pinto AK; Brien JD; Richner JM
J Virol; 2021 May; 95(12):. PubMed ID: 33762420
[TBL] [Abstract][Full Text] [Related]
12. Natural strain variation and antibody neutralization of dengue serotype 3 viruses.
Wahala WM; Donaldson EF; de Alwis R; Accavitti-Loper MA; Baric RS; de Silva AM
PLoS Pathog; 2010 Mar; 6(3):e1000821. PubMed ID: 20333252
[TBL] [Abstract][Full Text] [Related]
13. Engineered Dengue Virus Domain III Proteins Elicit Cross-Neutralizing Antibody Responses in Mice.
Frei JC; Wirchnianski AS; Govero J; Vergnolle O; Dowd KA; Pierson TC; Kielian M; Girvin ME; Diamond MS; Lai JR
J Virol; 2018 Sep; 92(18):. PubMed ID: 29976679
[TBL] [Abstract][Full Text] [Related]
14. B Cell Responses during Secondary Dengue Virus Infection Are Dominated by Highly Cross-Reactive, Memory-Derived Plasmablasts.
Priyamvada L; Cho A; Onlamoon N; Zheng NY; Huang M; Kovalenkov Y; Chokephaibulkit K; Angkasekwinai N; Pattanapanyasat K; Ahmed R; Wilson PC; Wrammert J
J Virol; 2016 Jun; 90(12):5574-85. PubMed ID: 27030262
[TBL] [Abstract][Full Text] [Related]
15. Analyzing the Human Serum Antibody Responses to a Live Attenuated Tetravalent Dengue Vaccine Candidate.
Swanstrom JA; Henein S; Plante JA; Yount BL; Widman DG; Gallichotte EN; Dean HJ; Osorio JE; Partidos CD; de Silva AM; Baric RS
J Infect Dis; 2018 May; 217(12):1932-1941. PubMed ID: 29800370
[TBL] [Abstract][Full Text] [Related]
16. The human antibody response to dengue virus infection.
Wahala WM; Silva AM
Viruses; 2011 Dec; 3(12):2374-95. PubMed ID: 22355444
[TBL] [Abstract][Full Text] [Related]
17. The potent and broadly neutralizing human dengue virus-specific monoclonal antibody 1C19 reveals a unique cross-reactive epitope on the bc loop of domain II of the envelope protein.
Smith SA; de Alwis AR; Kose N; Harris E; Ibarra KD; Kahle KM; Pfaff JM; Xiang X; Doranz BJ; de Silva AM; Austin SK; Sukupolvi-Petty S; Diamond MS; Crowe JE
mBio; 2013 Nov; 4(6):e00873-13. PubMed ID: 24255124
[TBL] [Abstract][Full Text] [Related]
18. Potent Neutralizing Human Monoclonal Antibodies Preferentially Target Mature Dengue Virus Particles: Implication for Novel Strategy for Dengue Vaccine.
Tsai WY; Chen HL; Tsai JJ; Dejnirattisai W; Jumnainsong A; Mongkolsapaya J; Screaton G; Crowe JE; Wang WK
J Virol; 2018 Dec; 92(23):. PubMed ID: 30185598
[TBL] [Abstract][Full Text] [Related]
19. Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions.
de Alwis R; Smith SA; Olivarez NP; Messer WB; Huynh JP; Wahala WM; White LJ; Diamond MS; Baric RS; Crowe JE; de Silva AM
Proc Natl Acad Sci U S A; 2012 May; 109(19):7439-44. PubMed ID: 22499787
[TBL] [Abstract][Full Text] [Related]
20. Dengue Virus prM-Specific Human Monoclonal Antibodies with Virus Replication-Enhancing Properties Recognize a Single Immunodominant Antigenic Site.
Smith SA; Nivarthi UK; de Alwis R; Kose N; Sapparapu G; Bombardi R; Kahle KM; Pfaff JM; Lieberman S; Doranz BJ; de Silva AM; Crowe JE
J Virol; 2016 Jan; 90(2):780-9. PubMed ID: 26512092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
